TCGA-CU-A3YL-01A-11R-A22U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 29.76346912
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.270
- HEDGEHOG_SIGNALING+0.160
- PANCREAS_BETA_CELLS+0.120
- WNT_BETA_CATENIN_SIGNALING+0.100
- MYOGENESIS+0.060
- APICAL_SURFACE+0.020
- ESTROGEN_RESPONSE_EARLY+0.020
- BILE_ACID_METABOLISM-0.070
- SPERMATOGENESIS-0.100
- ESTROGEN_RESPONSE_LATE-0.130
Top 10 suppressed
- MYC_TARGETS_V1-0.650
- MTORC1_SIGNALING-0.540
- MYC_TARGETS_V2-0.530
- UNFOLDED_PROTEIN_RESPONSE-0.530
- E2F_TARGETS-0.520
- OXIDATIVE_PHOSPHORYLATION-0.490
- PROTEIN_SECRETION-0.490
- G2M_CHECKPOINT-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- FATTY_ACID_METABOLISM-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A3Y1-01A-11R-A22U-07 | — | — | 0.952 |
| 2 | SRR12696743 | — | — | 0.944 |
| 3 | BS_90B22NGP | ATRT | — | 0.943 |
| 4 | SRR12696737 | — | — | 0.943 |
| 5 | SRR1478032 | GTEX | — | 0.943 |
| 6 | SRR4195693 | — | — | 0.941 |
| 7 | MNG226 | — | — | 0.940 |
| 8 | SRR602927 | GTEX | — | 0.939 |
| 9 | SRR1797298 | — | cohortSC | 0.938 |
| 10 | BS_0T17SY47 | low-grade glioma | — | 0.938 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.020 | Inavolisib | — uncovered |